Please login to the form below

Not currently logged in
Email:
Password:

Alnylam

This page shows the latest Alnylam news and features for those working in and with pharma, biotech and healthcare.

The year of the blockbuster

The year of the blockbuster

It is expected to become the first FDA-approved RNAi therapeutic following Alnylam’s completion of its new drug application (NDA) submission in December 2017. ... Together with the Genzyme unit of Sanofi, Alnylam filed for EU approval that same month.

Latest news

  • Pfizer drug gets speedy FDA review for rare heart failure complication Pfizer drug gets speedy FDA review for rare heart failure complication

    shares in both Alnylam and Ionis took a dive when it reported its phase III data earlier this year. ... A further wrinkle is that Alnylam’s trials only enrolled subjects with hereditary ATTR, while Pfizer’s studies included both hereditary and ‘wild

  • FDA lifts clinical hold on Sanofi’s haemophilia drug FDA lifts clinical hold on Sanofi’s haemophilia drug

    A major obstacle facing Sanofi and Alnylam’s haemophilia therapy fitusiran has been removed, after the FDA lifted a clinical hold imposed on the programme in September. ... use to 140, 000 patients in its licensed territories – but particularly for

  • Alnylam takes off on APOLLO trial results Alnylam takes off on APOLLO trial results

    Alnylam takes off on APOLLO trial results. Provides first late-stage evidence on the biotech's gene-silencing platform. ... Shares in RNA interference specialist Alnylam are rocketing ahead after the APOLLO trial provided its first late-stage win, and

  • Ionis says rare disease drug works, but safety concerns linger Ionis says rare disease drug works, but safety concerns linger

    Investors were spooked by the risks and Ionis shares declined 11%, while rival Alnylam - which is expecting phase III results for its FAP therapy patisiran in the coming months - rose 13%. ... Alnylam dropped lead amyloidosis drug revusiran last year

  • Novo Nordisk invests £115m in Oxford diabetes unit Novo Nordisk invests £115m in Oxford diabetes unit

    Last July, GlaxoSmithKline (GSK) pledged a £275m investment in its UK manufacturing facilities, while Alnylam has said it will set up its European headquarters in the country.

More from news
Approximately 7 fully matching, plus 27 partially matching documents found.

Latest Intelligence

  • Brexit: the facts (and the alternative facts) Brexit: the facts (and the alternative facts)

    Two post-referendum announcements have boosted the UK Government. GSK announced a £275 million investment in its UK manufacturing sites and Alnylam, a US biotech worth $6.5bn, said it would

  • Managing value: Why early asset development and commercialisation are important Managing value: Why early asset development and commercialisation are important

    For example, Alnylam Pharmaceuticals, with its lead product in phase III, has a market capitalisation of $7.4bn, despite having no marketed products; or Achillion Pharmaceuticals with a market capitalisation of

  • Deal Watch table for January 2014 Deal Watch table for January 2014

    Alnylam/ Genzyme. Extended agreement. Additional markets for patisiran and 3 pipeline products with option to all rare disease products. ... 300. Merck/Alnylam. Divestment. Sale of Merck's RNAi therapeutics unit Sirna. 290.

  • Pharma deals during January 2014 Pharma deals during January 2014

    One of the key players was Alnylam which had double news to impart last month. ... The other deal announced by Alnylam was the expansion of its deal with Sanofi (Genzyme unit_ to develop RNAi therapeutics in rare diseases.

  • Pharma deals during November 2012 Pharma deals during November 2012

    100. Tekmira / Alnylam. Patent settlement. Lipid nanoparticle (LNP) technology. 75.

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest appointments

  • Editas Medicine adds to board of directors Editas Medicine adds to board of directors

    Editas Medicine adds to board of directors. Alnylam Pharmaceuticals’ Dr Akshay Vaishnaw joins. ... He has extensive clinical development experience, a passion for scientific excellence, and achieved significant accomplishments as part of the leadership

  • VC firm expands team, appoints Genzyme and Lilly veterans VC firm expands team, appoints Genzyme and Lilly veterans

    The firm, which focuses on building healthcare companies, has appointed former executives from Genzyme, Lilly, ImClone and Alnylam to help it translate scientific innovation into new companies. ... Also joining Third Rock as venture partners are Daniel

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
EY Life Sciences

Our global reach Against a backdrop of regulatory, digital, financial and global transformation, Life Sciences companies are finding integration and...

Latest intelligence

GDPR and events. What does the pharma industry need to know?
...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...

Infographics